Translational Biomedicine

  • ISSN: 2172-0479
  • Journal h-index: 18
  • Journal CiteScore: 5.91
  • Journal Impact Factor: 4.11
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
Awards Nomination 20+ Million Readerbase
Indexed In
  • Open J Gate
  • Genamics JournalSeek
  • JournalTOCs
  • ResearchBible
  • The Global Impact Factor (GIF)
  • China National Knowledge Infrastructure (CNKI)
  • CiteFactor
  • Scimago
  • Electronic Journals Library
  • Directory of Research Journal Indexing (DRJI)
  • OCLC- WorldCat
  • Proquest Summons
  • Publons
  • MIAR
  • University Grants Commission
  • Geneva Foundation for Medical Education and Research
  • Google Scholar
  • Secret Search Engine Labs
  • ResearchGate
Share This Page


Impacts of Translational Biomedicine

William Robert*

The family of interferon (IFN) proteins has now quite reached the potential envisioned by early discovering virologists: IFNs aren't only antivirals with a spectrum of clinical effectiveness against both RNA and DNA viruses, but also are the prototypic biological response modifiers for oncology, and show effectiveness in suppressing manifestations of MS. The invention and molecular understanding of the cellular mechanisms and clinical use of interferon (IFNs) has been a serious advance in biomedicine over the past 50 years. This family of secreted anticrime and paracrine proteins stimulates intracellular and intercellular networks that regulate resistance to viral infections, enhance innate and purchased immune responses, and modulate normal and tumor cell survival and death.